These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005). Souayah N; Nasar A; Suri MF; Qureshi AI J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016 [TBL] [Abstract][Full Text] [Related]
47. Communicating the benefits and risks of vaccines. Kimmel SR; Wolfe RM J Fam Pract; 2005 Jan; 54(1 Suppl):S51-7. PubMed ID: 15623394 [TBL] [Abstract][Full Text] [Related]
52. [Recent changes in the epidemiology of infectious diseases in the Netherlands: the report 'Status of infectious diseases in the Netherlands, 2000-2005']. Rahamat-Langendoen JC; van Vliet JA Ned Tijdschr Geneeskd; 2007 Jun; 151(24):1333-8. PubMed ID: 17665624 [TBL] [Abstract][Full Text] [Related]
53. Routine and recommended vaccinations for travellers. Duszczyk E; Talarek E Int Marit Health; 2008; 59(1-4):116-23. PubMed ID: 19227745 [TBL] [Abstract][Full Text] [Related]
54. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Nicolas JF; Guy B Expert Rev Vaccines; 2008 Oct; 7(8):1201-14. PubMed ID: 18844594 [TBL] [Abstract][Full Text] [Related]
55. Communicating vaccine safety to the media and general public. Oubari H; Tuttle R; Rath B; Bravo L Curr Drug Saf; 2015; 10(1):80-6. PubMed ID: 25859680 [TBL] [Abstract][Full Text] [Related]
56. [Imported diseases: information, communication and continuing education]. Degrémont A Ther Umsch; 1990 Oct; 47(10):839-43. PubMed ID: 2260025 [TBL] [Abstract][Full Text] [Related]
57. Which pharmacovigilance for vaccines? Le Louët H; Loupi E; Haramburu F; Therapie; 2007; 62(3):241-7. PubMed ID: 17803893 [TBL] [Abstract][Full Text] [Related]
58. Scientists worry about some risks more than the public. Scheufele DA; Corley EA; Dunwoody S; Shih TJ; Hillback E; Guston DH Nat Nanotechnol; 2007 Dec; 2(12):732-4. PubMed ID: 18654416 [No Abstract] [Full Text] [Related]
59. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. Patel MM; Parashar UD J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612 [TBL] [Abstract][Full Text] [Related]
60. Regulations and procedures in parasite vaccine development. Schetters TP; Gravendyck M Parasitology; 2006; 133 Suppl():S189-95. PubMed ID: 17274846 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]